Evidence map›Paper›PMID 35120450›Full record

ArticleBMC genomics2022

Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia.

María Pagnon de la Vega, Carl Näslund, RoseMarie Brundin, Lars Lannfelt, Malin Löwenmark, Lena Kilander, Martin Ingelsson, Vilmantas Giedraitis

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

María Pagnon de la VegaDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
Carl NäslundDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
RoseMarie BrundinDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
Lars LannfeltDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
Malin LöwenmarkDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
Lena KilanderDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
Martin IngelssonDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
Vilmantas GiedraitisDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden. vilmantas.giedraitis@pubcare.uu.se.
Uppsala University · SEUniversity of Toronto · CA

Funding

Vetenskapsrådet 2016-02120
6 · The paper itself

Abstract

backgroundMost dementia disorders have a clear genetic background and a number of disease genes have been identified. Mutations in the tau gene (MAPT) lead to frontotemporal dementia (FTD), whereas mutations in the genes for the amyloid-β precursor protein (APP) and the presenilins (PSEN1, PSEN2) cause early-onset, dominantly inherited forms of Alzheimer's disease (AD). Even if mutations causing Mendelian forms of these diseases are uncommon, elucidation of the pathogenic effects of such mutations have proven important for understanding the pathogenic processes. Here, we performed a screen to identify novel pathogenic mutations in known disease genes among patients undergoing dementia investigation.

resultsUsing targeted exome sequencing we have screened all coding exons in eleven known dementia genes (PSEN1, PSEN2, APP, MAPT, APOE, GRN, TARDBP, CHMP2B, TREM2, VCP and FUS) in 102 patients with AD, FTD, other dementia diagnoses or mild cognitive impairment. We found three AD patients with two previously identified pathogenic mutations in PSEN1 (Pro264Leu and Met146Val). In this screen, we also identified the recently reported APP mutation in two siblings with AD. This mutation, named the Uppsala mutation, consists of a six amino acid intra-amyloid β deletion. In addition, we found several potentially pathogenic mutations in PSEN2, FUS, MAPT, GRN and APOE. Finally, APOE ε4 was prevalent in this patient group with an allele frequency of 54%.

conclusionsAmong the 102 screened patients, we found two disease causing mutations in PSEN1 and one in APP, as well as several potentially pathogenic mutations in other genes related to neurodegenerative disorders. Apart from giving important information to the clinical investigation, the identification of disease mutations can contribute to an increased understanding of disease mechanisms.

Indexed as

Alzheimer DiseaseFrontotemporal DementiaAmyloid beta-PeptidesHumansMembrane GlycoproteinsMutationPresenilin-1Presenilin-2Receptors, ImmunologicAmyloid beta-PeptidesMembrane GlycoproteinsPresenilin-1Presenilin-2Receptors, ImmunologicTREM2 protein, humanAlzheimer's diseaseAPOEAPPExome sequencingFrontotemporal dementiaMAPTNeurodegenerative disordersPSEN1PSEN2

Identifiers

PMID35120450
PMCPMC8817590
OpenAlexW3197196408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.